ARTICLE | Clinical News
Trumenba regulatory update
May 30, 2016 7:00 AM UTC
EMA accepted for review an MAA from Pfizer for Trumenba to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in individuals ages >=10. In 2014, FDA granted accelerate...